Overview

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Status:
Active, not recruiting

Trial end date:
2025-01-31

Target enrollment:

Participant gender:

Summary

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: - Itacitinib (INCB039110) - Dabrafenib - Trametinib

Phase:

Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Incyte Corporation
Incyte Pharmaceuticals

Treatments:

Dabrafenib
Trametinib